GlassScriptPhysician profile
Sherry D Azar
NPI 1528050788
$2,037.96
in general payments reported to CMS, 2019-2025
33 companies · $212 in 2025
The $212 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $63.99 · 2022: $195 · 2023: $576 · 2024: $991 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,779.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $184.02 | 2023-2025 | Alunbrig, Ninlaro, Vpriv |
| Astrazeneca Pharmaceuticals LP | $160.32 | 2023 | Calquence |
| Incyte Corporation | $116.11 | 2023-2024 | Jakafi, Monjuvi, Pemazyre |
| Daiichi Sankyo INC. | $103.39 | 2022-2024 | Enhertu, Injectafer |
| Novartis Pharmaceuticals Corporation | $102.63 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $96.77 | 2023-2024 | Keytruda, Lynparza |
| Astellas Pharma US INC | $87.51 | 2023-2024 | Xospata, Xtandi |
| Celgene Corporation | $79.74 | 2022-2024 | Reblozyl, Pomalyst |
| Mallinckrodt Hospital Products INC. | $79.47 | 2021-2022 | |
| Glaxosmithkline, LLC. | $78.50 | 2023-2024 | Ojjaara, Shingrix |
| Taiho Oncology, INC. | $74.93 | 2024-2025 | |
| Eisai INC. | $71.46 | 2023-2024 | |
| Beigene USA, INC. | $67.26 | 2024-2025 | Brukinsa |
| Rigel Pharmaceuticals, INC. | $62.24 | 2024 | Tavalisse, Rezlidhia |
| Janssen Biotech, INC. | $61.62 | 2022-2023 | Imbruvica |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $58.13 | 2023-2025 | Jaypirca, Verzenio |
| Sobi, INC | $58.12 | 2024 | |
| Legend Biotech USA INC. | $56.29 | 2024-2025 | Carvykti |
| Abbvie INC. | $56.11 | 2024 | |
| Genzyme Corporation | $40.10 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.03 | 2022 | |
| Genentech USA, INC. | $38.92 | 2023 | Columvi, Polivy, Phesgo |
| Kyowa Kirin, INC. | $29.37 | 2024 | Poteligeo |
| Alexion Pharmaceuticals, INC. | $26.18 | 2024 | Ultomiris |
| Adc Therapeutics America, INC. | $25.79 | 2024 | |
| Genmab U.S., INC. | $25.20 | 2024 | Epkinly |
| Pharmaessentia USA Corporation | $24.45 | 2024 | Besremi |
| Pfizer INC. | $23.56 | 2024 | |
| Mirati Therapeutics, INC. | $23.49 | 2023 | Krazati |
| Horizon Therapeutics Plc | $23.06 | 2022 | |
| Tersera Therapeutics LLC | $22.78 | 2024 | Quzyttir |
| Pharmacosmos Therapeutics INC. | $21.81 | 2023 | Monoferric |
| Kite Pharma, INC. | $18.60 | 2023 | Yescarta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherry Azar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.